visitante ::
identificación
|
|||||||||||||||
Buscar | Enviar | Ayuda | Servicio de Bibliotecas | Sobre el DDD | Català English Español |
Página principal > Artículos > Artículos publicados > Predicting long-term disease control in transplant-ineligible patients with multiple myeloma : |
Fecha: | 2019 |
Resumen: | Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18. 6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60. 8% as compared with 11. 8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2. 74, p = 0. 001) and MGUS-like profile (OR 4. 18, p = 0. 005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2. 27) and MGUS-like signature (OR 7. 48) retained their predictive value along with MRD negativity (OR 5. 18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18. 6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years. |
Ayudas: | Instituto de Salud Carlos III CB16-12-00369 Instituto de Salud Carlos III CB16-12-00377 Instituto de Salud Carlos III PS09-01897-01370 Instituto de Salud Carlos III PI12-01761 Instituto de Salud Carlos III PI12-02311 Instituto de Salud Carlos III PI13-01469 Instituto de Salud Carlos III PI14-01867 Instituto de Salud Carlos III G03-136 Instituto de Salud Carlos III CD13-00340 |
Nota: | Altres ajuts: This study was supported by the Asociación Española Contra el Cáncer (GCB120981SAN) and the European Research Council (ERC) 2015 Starting Grant (MYELOMANEXT). |
Derechos: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Lengua: | Anglès |
Documento: | Article ; recerca ; Versió publicada |
Materia: | Aged ; Female ; Humans ; Male ; Monoclonal Gammopathy of Undetermined Significance ; Multiple Myeloma |
Publicado en: | Blood Cancer Journal, Vol. 9 Núm. 4 (january 2019) , p. 36, ISSN 2044-5385 |
6 p, 359.1 KB |